Ketoconazole

Generic Name: Ketoconazole

Brand Names: Extina, Ketodan, Ketoderm, Nizoral, Xolegel, Ketoconazole HRA

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₂₈Cl_₂N_₄O_₄

CAS Number: 65277-42-1

Unique Ingredient Identifier: R9400W927I

Background: Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections. It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus. Ketoconazole was first approved in an oral formulation for systemic use by...

Indication: Ketoconazole is used in the treatment or prevention of fungal infections including blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. In Europe, it is also used in the treatment of endogenous Cushing's syndrome.

Associated Conditions: Bacterial Vaginosis (BV), Blastomycosis, Candidiasis, Systemic, Chromoblastomycosis, Chronic Mucocutaneous Candidiasis (CMC), Coccidioidomycosis, Dandruff, Endogenous Cushing's Syndrome, Fungal Infections, Histoplasmosis, Paracoccidioidomycosis, Seborrheic Dermatitis, Tinea Corporis caused by Epidermophyton floccosumin, Tinea Corporis caused by Trichophyton mentagrophytes, Tinea Corporis caused by Trichophyton rubrum, Tinea Cruris caused by Epidermophyton floccosumin, Tinea Cruris caused by Trichophyton mentagrophytes, Tinea Cruris caused by Trichophyton rubrum, Tinea Pedis caused by Epidermophyton floccosumin, Tinea Pedis caused by Trichophyton mentagrophytes, Tinea Pedis caused by Trichophyton rubrum, Vaginal Candidiasis, Vulvovaginal Candidiasis, Cutaneous candidiasis, Recalcitrant Dermatophytosis, Tinea versicolor caused by Malassezia infection

Associated Therapies: -

Clinical Trials

ANI Pharmaceuticals launches generic Ketoconazole Shampoo

ANI Pharmaceuticals launches Ketoconazole Shampoo, 2%, following FDA approval, aiming to address unmet medical needs and expand its generics business. The company also completed the acquisition of Alimera Sciences, broadening its ophthalmology portfolio, and reported a robust Q2 2024 with a revenue increase of 18% to $138 million, driven by its rare disease asset and generics business. ANI Pharmaceuticals' market capitalization is $1.12 billion, with a 34.27% revenue growth over the last twelve months and a gross profit margin of 61.34%.

finance.yahoo.com

3 months ago

ANI Pharmaceuticals Announces the FDA Approval and Launch of Ketoconazole Shampoo, 2%

ANI Pharmaceuticals launched Ketoconazole Shampoo, 2% after FDA approval, aiming to address patient needs with limited competition. The product is a generic version of Nizoral®, with U.S. annual sales estimated at $69.2 million.

globenewswire.com

3 months ago

ANI Pharmaceuticals Announces the FDA Approval and Launch

ANI Pharmaceuticals launched Ketoconazole Shampoo, 2% after FDA approval, aiming to address patient needs with another limited competition product. U.S. annual sales for the shampoo are approximately $69.2 million.

Ketoconazole

ANI Pharmaceuticals launches generic Ketoconazole Shampoo

ANI Pharmaceuticals Announces the FDA Approval and Launch of Ketoconazole Shampoo, 2%

ANI Pharmaceuticals Announces the FDA Approval and Launch

Drug Development Updates